Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer

References

• Audiger C, Rahman MJ, Yun TJ, Tarbell KV, Lesage S. The importance of dendritic cells in maintaining immune tolerance. J Immunol. 2017;198(6):2223–14. doi:10.4049/jimmunol.1601629.
   PubMed Web of Science ®Google Scholar
• Mutyambizi K, Berger CL, Edelson RL. The balance between immunity and tolerance: the role of Langerhans cells. Cell Mol Life Sci. 2009;66:831–840. doi:10.1007/s00018-008-8470-y.
   PubMed Web of Science ®Google Scholar
• Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs. 2019;79(11):1231–1239. doi:10.1007/s40265-019-01158-1.
   PubMed Web of Science ®Google Scholar
• Markman M. The evolving arena of ovarian cancer maintenance therapy. Oncology. 2019;97:202–205.
   Web of Science ®Google Scholar
• Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. (2019);11:1179299X19860815. doi:10.1177/1179299X19860815.
   PubMedGoogle Scholar
• Armbruster S, Coleman RL, Rauh-Hain JA. Management and treatment of recurrent epithelial ovarian cancer. Hematol Oncol Clin North Am. (2018);32(6):965–982. doi:10.1016/j.hoc.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. (2002);7(Suppl 5):20–28. doi:10.1634/theoncologist.7-suppl_5-20.
   PubMed Web of Science ®Google Scholar
• Onnis A. The management of ovarian cancer: an update. Eur J Gynaecol Oncol. 1997;18:157–160.
   PubMed Web of Science ®Google Scholar
• Chu CS, Rubin SC. Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep. 2001;3(1):11–18. doi:10.1007/s11912-001-0037-0.
   PubMedGoogle Scholar
• Alvero AB, Montagna MK, Craveiro V, Liu L, Mor G. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol. 2012;67(3):256–265. doi:10.1111/j.1600-0897.2011.01068.x.
   PubMed Web of Science ®Google Scholar
• Gimotty PA, Zhang L, Alagkiozidis I, Cadungog M, Adams S, Chu C, Katsaros D, Coukos G. Immune prognostic factors in ovarian cancer: lessons from translational research. Dis Markers. 2007;23(5–6):445–452. doi:10.1155/2007/508350.
   PubMed Web of Science ®Google Scholar
• Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G. Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. Oncoimmunology. 2016;5(5):e1062210. doi:10.1080/2162402X.2015.1062210.
   PubMed Web of Science ®Google Scholar
• Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I, Coosemans A. Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer. Front Immunol. 2019;10:1273. doi:10.3389/fimmu.2019.01273.
   PubMed Web of Science ®Google Scholar
• Walankiewicz M, Grywalska E, Polak G, Kotarski J, Siwicka-Gieroba DJ, Roliński J. Myeloid-derived suppressor cells in ovarian cancer: friend or foe? Cent Eur J Immunol. 2017;42(4):383–389. doi:10.5114/ceji.2017.72823.
   PubMed Web of Science ®Google Scholar
• Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell. 2018;173(7):1755–1769 e1722. doi:10.1016/j.cell.2018.03.073.
   PubMed Web of Science ®Google Scholar
• Raghavan S, Mehta P, Xie Y, Lei YL, Mehta G. Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer. 2019;7(1):190. doi:10.1186/s40425-019-0666-1.
   PubMed Web of Science ®Google Scholar
• Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3(1):11. doi:10.1186/s40661-016-0033-6.
   PubMedGoogle Scholar
• Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: a Phase I study. Leuk Lymphoma. 2006;47(8):1495–1503. doi:10.1080/10428190600581419.
   PubMed Web of Science ®Google Scholar
• Edelson R, Wu Y, Schneiderman J. American council on ECP (ACE): why now? J Clin Apher. 2018;33(4):464–468. doi:10.1002/jca.21627.
   PubMed Web of Science ®Google Scholar
• Raval JS, Ratcliffe NR. Extracorporeal photopheresis and personalized medicine in the 21st century: the future’s so bright! J Clin Apher. 2018;33(4):461–463. doi:10.1002/jca.21633.
   PubMed Web of Science ®Google Scholar
• Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, Bonney D, Das-Gupta E, Lawson S, Malladi RK. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol. 2017;177(2):287–310. doi:10.1111/bjh.14537.
   PubMed Web of Science ®Google Scholar
• Dunbar NM, Raval JS, Johnson A, Abikoff CM, Adamski J, Cooling LL, Grossman B, Kim HC, Marques MB, Morgan S. Extracorporeal photopheresis practice patterns: an international survey by the ASFA ECP subcommittee. J Clin Apher. 2017;32(4):215–223. doi:10.1002/jca.21486.
   PubMed Web of Science ®Google Scholar
• Durazzo TS, Tigelaar RE, Filler R, Hayday A, Girardi M, Edelson RL. Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. Transfus Apher Sci. 2014;50:370–378. doi:10.1016/j.transci.2013.11.008.
   PubMed Web of Science ®Google Scholar
• Edelson RL. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfusion Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis. 2014;50(3):322–329. doi:10.1016/j.transci.2013.07.031.
   PubMed Web of Science ®Google Scholar
• Kibbi N, Sobolev O, Girardi M, Edelson RL. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfusion Apheresis Sci: Off J World Apheresis Assoc: Off J Eur Soc Haemapheresis. 2016;55(1):146–152. doi:10.1016/j.transci.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Edelson RL. Transimmunization: the science catches up to the clinical success. Transfus Apher Sci. 2002;26(3):177–180. doi:10.1016/S1473-0502(02)00010-1.
   PubMed Web of Science ®Google Scholar
• Girardi M, Berger C, Hanlon D, Edelson RL. Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization. Technol Cancer Res Treat. 2002;1(1):65–69. doi:10.1177/153303460200100109.
   PubMed Web of Science ®Google Scholar
• Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O. Novel protocol for generating physiologic immunogenic dendritic cells. J Visualized Exp: JoVE. 2019;147. 10.3791/59370
   PubMed Web of Science ®Google Scholar
• Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, et al. Extracorporeal photochemotherapy drives monocyte-to-dendritic cell maturation to induce anticancer immunity. Cancer Res. 2018;78(14):4045–4058. doi:10.1158/0008-5472.CAN-18-0171.
   PubMed Web of Science ®Google Scholar
• Tatsuno K, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A, Rivera-Molina F, Arshad N, Edelson RL. Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death Dis. 2019;10(8):578. doi:10.1038/s41419-019-1819-3.
   PubMed Web of Science ®Google Scholar
• Kim J, Coffey DM, Ma L, Matzuk MM. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. Endocrinology. 2015;156(6):1975–1981. doi:10.1210/en.2014-1977.
   PubMed Web of Science ®Google Scholar
• Craveiro V, Yang-Hartwich Y, Holmberg JC, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi D-A, Azodi M, Rutherford T. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med. (2013);2(6):751–762. doi:10.1002/cam4.115.
   PubMed Web of Science ®Google Scholar
• Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res. (2016);29(5):590–597. doi:10.1111/pcmr.12498.
   PubMed Web of Science ®Google Scholar
• Alvero AB, Heaton A, Lima E, Pitruzzello M, Sumi N, Yang-Hartwich Y, Cardenas C, Steinmacher S, Silasi D-A, Brown D. TRX-E-002-1 induces c-Jun–Dependent apoptosis in ovarian cancer stem cells and prevents recurrence in vivo. Mol Cancer Ther. 2016;15(6):1279–1290. doi:10.1158/1535-7163.MCT-16-0005.
   PubMed Web of Science ®Google Scholar
• Alvero AB, Kim D, Lima E, Sumi NJ, Lee JS, Cardenas C, Pitruzzello M, Silasi D-A, Buza N, Fahmy T. Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model. Sci Rep. 2017;7(1):40989. doi:10.1038/srep40989.
   PubMed Web of Science ®Google Scholar
• Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4(7):e6412. doi:10.1371/journal.pone.0006412.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213. doi:10.1056/NEJMoa020177.
   PubMed Web of Science ®Google Scholar
• Radestad E, Klynning C, Stikvoort A, Mogensen O, Nava S, Magalhaes I, Uhlin M. Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncoimmunology. 2019;8(2):e1535730. doi:10.1080/2162402X.2018.1535730.
   PubMed Web of Science ®Google Scholar
• Ouzounova M, Lee E, Piranlioglu R, El Andaloussi A, Kolhe R, Demirci MF, Marasco D, Asm I, Chadli A, Hassan KA. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat Commun. 2017;8(1):14979. doi:10.1038/ncomms14979.
   PubMed Web of Science ®Google Scholar
• Shiue LH, Couturier J, Lewis DE, Wei C, Ni X, Duvic M. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4+ Foxp3 + CD25 T cells in patients with leukemic cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed. (2015);31(4):184–194. doi:10.1111/phpp.12175.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386.
   PubMed Web of Science ®Google Scholar
• Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016;113(48):E7759–e7768. doi:10.1073/pnas.1609376113.
   PubMed Web of Science ®Google Scholar
• Clarke B, Tinker AV, Lee C-H, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402. doi:10.1038/modpathol.2008.191.
   PubMed Web of Science ®Google Scholar
• Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–198. doi:10.1016/j.ygyno.2011.09.039.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget. 2017;8(9):15621–15631. doi:10.18632/oncotarget.14919.
   PubMedGoogle Scholar
• Fan CA, Reader J, Roque DM. Review of immune therapies targeting ovarian cancer. Curr Treat Options Oncol. 2018;19(12):74. doi:10.1007/s11864-018-0584-3.
   PubMed Web of Science ®Google Scholar
• Marth C, Wieser V, Tsibulak I, Zeimet AG. Immunotherapy in ovarian cancer: fake news or the real deal? Int J Gynecol Cancer. 2019;29(1):201–211. doi:10.1136/ijgc-2018-000011.
   PubMed Web of Science ®Google Scholar
• Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28:viii1–viii7. doi:10.1093/annonc/mdx444.
   PubMed Web of Science ®Google Scholar
• Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE. NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome. Clin Cancer Res. (2018);24(5):1019–1029. doi:10.1158/1078-0432.CCR-17-1792.
   PubMed Web of Science ®Google Scholar
• Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A, Chiappinelli KB. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):7. doi:10.1186/s13148-018-0602-0.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T,Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014;2:37–49. doi:10.1158/2326-6066.CIR-13-0126.
   PubMed Web of Science ®Google Scholar
• Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947. doi:10.3389/fimmu.2018.00947.
   PubMed Web of Science ®Google Scholar
• Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, Utikal J. Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. 2017;39(3):295–305. doi:10.1007/s00281-016-0597-6.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268. doi:10.1038/nri3175.
   PubMed Web of Science ®Google Scholar
• De Sanctis F, Solito S, Ugel S, Molon B, Bronte V, Marigo I. “MDSCs in cancer: conceiving new prognostic and therapeutic targets.” Biochim Biophys Acta. (2016);1865(1):35–48. doi:10.1016/j.bbcan.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res. 2015;128:95–139.
   PubMed Web of Science ®Google Scholar
• Okla K, Czerwonka A, Wawruszak A, Bobiński M, Bilska M, Tarkowski R, Bednarek W, Wertel I, Kotarski J. Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer. Front Immunol. 2019;10:691. doi:10.3389/fimmu.2019.00691.
   PubMed Web of Science ®Google Scholar
• Santegoets S, de Groot AF, Dijkgraaf EM, Simões AMC, van der Noord VE, van Ham JJ, Welters MJP, Kroep JR, van der Burg SH. The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival. Oncoimmunology. 2018;7:e1465166. doi:10.1080/2162402X.2018.1465166.
   PubMed Web of Science ®Google Scholar
• Pastaki Khoshbin A, Eskian M, Keshavarz-Fathi M, Rezaei N. “Roles of myeloid-derived suppressor cells in cancer metastasis: immunosuppression and beyond. Arch Immunol Ther Exp (Warsz). 2019;67:89–102. doi:10.1007/s00005-018-0531-9.
   PubMed Web of Science ®Google Scholar
• Sijmons EA, Heintz AP. Second-look and second surgery: second chance or second best? Semin Surg Oncol. 2000;19(1):54–61. doi:10.1002/1098-2388(200007/08)19:1<54::AID-SSU9>3.0.CO;2-9.
   PubMedGoogle Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar